Mexiletine Metabolites: A Review

Author(s): Alessia Catalano, Alessia Carocci, Maria Stefania Sinicropi.

Journal Name: Current Medicinal Chemistry

Volume 22 , Issue 11 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Mexiletine belongs to class IB antiarrhythmic drugs and it is still considered a drug of choice for treating myotonias. However some patients do not respond to mexiletine or have significant side effects limiting its use; thus, alternatives to this drug should be envisaged. Mexiletine is extensive metabolized in humans via phase I and phase II reactions. Only a small fraction (about 10%) of the dose of mexiletine administered is recovered without modifications in urine. Although in the past decades Mex metabolites were reported to be devoid of biological activity, recent studies seem to deny this assertion. Actually, several hydroxylated metabolites showed pharmacological activity similar to that of Mex, thus contributing to its clinical profile. Purpose of this review is to summarize all the studies proposed till now about mexiletine metabolites, regarding structureactivity relationship studies as well as synthetic strategies. Biological and analytical studies will be also reported.

Keywords: Antiarrhythmic agents, antimyotonic agents, chiral switch, mexiletine, sodium channel blockers.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 22
ISSUE: 11
Year: 2015
Page: [1400 - 1413]
Pages: 14
DOI: 10.2174/0929867322666150227145412
Price: $58

Article Metrics

PDF: 26